Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients (UCMSC)
Efficacy and Safety of Normoxic Allogenic Umbilical Cord Mesenchymal Stem Cells Administered as Adjuntive Treatment to Standard Treatment in Severe Patients With COVID-19
Sponsor: Dr. Hasan Sadikin General Hospital, Bandung, Indonesia
Listed as NCT05132972, this PHASE2/PHASE3 trial focuses on Covid 19 and remains ongoing. Sponsored by Dr. Hasan Sadikin General Hospital, Bandung, Indonesia, it has been updated 4 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
Status: Recruiting → Unknown Status
-
Dec 2021 — Dec 2023 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Jan 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dr. Hasan Sadikin General Hospital, Bandung, Indonesia
- Dr. Moewardi General Hospital, Surakarta, Indonesia
- Dr. Sardjito General Hospital, Yogyakarta, Indonesia
- Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia
- PT Bifarma Adiluhung
For direct contact, visit the study record on ClinicalTrials.gov .